Teva Pharmaceutical Industries Limited Announces Launch Of Generic Wellbutrin XL(R) Tablets, 300 Mg Under Agreement With Anchen Pharmaceuticals(USA), Inc. And IMPAX Laboratories, Inc.

Published: Dec 18, 2006

JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has commercially shipped Bupropion Hydrochloride Extended-Release Tablets, 300 mg, the generic version of Biovail Corporation’s antidepressant Wellbutrin XL® Tablets, pursuant to an agreement with IMPAX Laboratories, Inc. (NASDAQ:IPXL) and Anchen Pharmaceuticals, Inc. Wellbutrin XL® Tablets, 300 mg, marketed by GlaxoSmithKline, had U.S. sales of approximately $972 million for the 12 months ended September 2006, according to IMS data.

Back to news